TRAPS-Syndrom ohne Nachweis einer Mutation im TNFRSF1A-Gen mit gutem Ansprechen auf Anakinra

• Literatur

• 1 Rigante D. et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol 2014; 33: 1197-1207.
• 2 Cattalini M. et al. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to anakinra. Dermatol Online J 2013; 19 (11) 20405.
• 3 Ter Haar N. et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-685.
• 4 Bulua AC. et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012; 64 (03) 908-913.
• 5 Cantarini L. et al. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 2010; 23 (03) 701-707.
• 6 Cantarini L. et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012; 12 (01) 38-43.
• 7 Migkos MP. et al. Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. Clin Exp Rheumatol. 2015 May 1. [Epub ahead of print].
• 8 Ter Haar NM. et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015; 74 (09) 1636-1644.